^
Association details:
| Biomarker: | CD19 positive |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Kymriah (tisagenlecleucel-T) (CD19-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Excerpt:
...tisagenlecleucel in pediatric and young adult patients with CD19+ relapsed or refractory B-cell ALL…The rates of event-free survival and overall survival were 73% (95% confidence interval [CI], 60 to 82) and 90% (95% CI, 81 to 95), respectively, at 6 months and 50% (95% CI, 35 to 64) and 76% (95% CI, 63 to 86) at 12 months.
DOI:
10.1056/NEJMoa1709866
Trial ID:
